- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02172352
Dose Ranging Study of Ba 679 BR Inhalation Powder in Chronic Obstructive Pulmonary Disease (COPD) Patients
June 20, 2014 updated by: Boehringer Ingelheim
Dose Ranging Study of Ba 679 BR Inhalation Powder Following Single Inhalation in COPD Patients - Double-blind, Placebo-controlled, 4 Treatment, 4 Period Crossover Study-
To investigate the dose response following single inhalation of Ba 679 BR inhalation powder in COPD patients using pulmonary functions as indicators, and to compare data obtained with overseas study findings
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
28
Phase
- Phase 2
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- In a pulmonary function test of Screening Test II, FEV1.0 was less than 70% of predict normal and FEV1.0 was less than 70% of FVC.
- In the reversibility test of Screening Test II, FEV1.0 was improved by 10% or more at 1 hour after inhalation of 2 puffs of an anticholinergic agent (Tersigan ® Aerozol)
- History of smoking (< no. of cigarettes a day x no. of years of smoking > = 200 or more)
- 40 years of age or older
- Regardless of sex and the length of disease period
Exclusion Criteria:
- A history of bronchial asthma
- A history of atopic disease, such as allergic rhinitis
- Blood eosinophil of 440/µl or more
- Continuous use of steroid drugs (oral administration, inhalation or injection) at a dose equivalent to over 5 mg daily of prednisolone
- A history of respiratory infection, including virus infection within 1 month before study initiation
- Tuberculosis, lung cancer or a history of pneumonectomy
- Glaucoma
- Under treatment of benign prostatic hypertrophy
- Hypersensitivity to anticholinergic agents or sympathomimetics
- Difficulty in expectoration of sputum
- Serious heart disease, renal disease, hepatic disease, endocrine disease or metabolic disease
- Use of any β blockers
- A history of myocardial infarction within the past 1 year
- A history of heart failure, cor pulmonale or arrhythmia requiring medication within the past 3 years
- A history of drug abuse or alcoholism
- Treatment of psychotic disease
- Pregnancy, possible pregnancy or lactation
- A history of participation in any other clinical studies within the past 6 months
- Judgment by the investigator that the patient is ineligible for inclusion in the present study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Ba 679 BR low dose
|
|
Placebo Comparator: Placebo inhalation powder
|
|
Experimental: Ba 679 BR middle dose
|
|
Experimental: Ba 679 BR high dose
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
FEV1.0 max (maximum forced expiratory volume in one second)
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
FEV1.0 AUC 0-24 (forced expiratory volume in one second as area under the curve 0 to 24 hours after administration)
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FEV1.0 time to response
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FEV1.0 Tmax (time to FEV1.0 max)
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FEV1.0 at measuring time points up to 24 hours after administration of study drug
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FVC AUC 0-24 (forced vital capacity as area under the curve 0 to 24 hours after administration)
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FVC max
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
FVC at measuring time points up to 24 hours after administration of study drug
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Occurrence of adverse events
Time Frame: up to 29 days
|
up to 29 days
|
Changes in blood pressure
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Changes in pulse rate
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Changes in transdermal O2 saturation
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Abnormal findings in electrocardiogram (ECG)
Time Frame: before and 1.5 and 24 hours after each administration of study drug
|
before and 1.5 and 24 hours after each administration of study drug
|
Abnormal changes in laboratory measurements
Time Frame: at 24 hours after last study drug administration
|
at 24 hours after last study drug administration
|
Urinary excretion rate
Time Frame: before (from 4 hours pre-dosing until immediately before dosing) and 0-2, 2-4, 4-8, 8-12 and 12-24 hours after drug administration
|
before (from 4 hours pre-dosing until immediately before dosing) and 0-2, 2-4, 4-8, 8-12 and 12-24 hours after drug administration
|
MMEF AUC 0-24 (maximal midexpiratory flow as area under the curve 0 to 24 hours after administration)
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
MMEF max
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
MMEF at measuring time points up to 24 hours after administration of study drug
Time Frame: before and up to 24 hours after each study drug administration
|
before and up to 24 hours after each study drug administration
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 1, 1998
Primary Completion (Actual)
May 1, 1999
Study Registration Dates
First Submitted
June 20, 2014
First Submitted That Met QC Criteria
June 20, 2014
First Posted (Estimate)
June 24, 2014
Study Record Updates
Last Update Posted (Estimate)
June 24, 2014
Last Update Submitted That Met QC Criteria
June 20, 2014
Last Verified
June 1, 2014
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Lung Diseases, Obstructive
- Lung Diseases
- Pulmonary Disease, Chronic Obstructive
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Parasympatholytics
- Autonomic Agents
- Peripheral Nervous System Agents
- Cholinergic Antagonists
- Cholinergic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Tiotropium Bromide
Other Study ID Numbers
- 205.139
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pulmonary Disease, Chronic Obstructive
-
Spire, Inc.ResMedCompletedSevere Chronic Obstructive Pulmonary Disease | Moderate Chronic Obstructive Pulmonary DiseaseUnited States
-
Karaganda Medical UniversityCompletedChronic Obstructive Pulmonary Disease | Chronic Obstructive Pulmonary Disease Moderate | Chronic Obstructive Pulmonary Disease SevereKazakhstan
-
Randall DebattistaUniversity of Malta, Faculty of Health SciencesNot yet recruitingChronic Obstructive Pulmonary Disease Moderate | Acute Exacerbation of COPD | Chronic Obstructive Pulmonary Disease Severe
-
Cukurova UniversityCompletedAnesthesia | Chronic Obstructive Pulmonary Disease Moderate | Lungcancer | Chronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease MildTurkey
-
National Taipei University of Nursing and Health...TerminatedChronic Pulmonary Disease | Chronic Obstructive Pulmonary Disease Exacerbation | Chronic Obstructive Pulmonary Disease With ExacerbationTaiwan
-
Taipei Medical UniversityUnknownChronic Obstructive Pulmonary Disease Severe | Chronic Obstructive Pulmonary Disease End StageTaiwan
-
Kırıkkale UniversityRecruitingCOPD (Chronic Obstructive Pulmonary Disease)Turkey
-
Hopital FochAir Liquide SARecruitingChronic Obstructive Pulmonary Disease SevereFrance
-
Fundación para la Investigación del Hospital Clínico...Not yet recruitingCOPD, Chronic Obstructive Pulmonary DiseaseSpain
-
Canandaigua VA Medical CenterRecruitingChronic Obstructive Pulmonary Disease ModerateUnited States
Clinical Trials on Ba 679 BR low dose
-
Pepperdine UniversityRecruitingHigh Nitrate Dose | Moderate Nitrate Dose | Low Nitrate Dose | Nitrate-depleted DoseUnited States
-
BioNTech SEPfizerWithdrawn
-
Boehringer IngelheimCompleted
-
Boehringer IngelheimCompletedPulmonary Disease, Chronic ObstructiveJapan
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
BioNTech SEPfizerRecruitingCOVID-19 | Severe Acute Respiratory Syndrome Coronavirus 2 | SARS-CoV-2 VirusUnited States, Brazil, Puerto Rico
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
WestVac Biopharma Co., Ltd.Not yet recruiting
-
Boehringer IngelheimCompleted